EP1274862A4 - Regulation d'un gene induit par des lipides oxydes dans des cellules humaines de paroi arterielle - Google Patents

Regulation d'un gene induit par des lipides oxydes dans des cellules humaines de paroi arterielle

Info

Publication number
EP1274862A4
EP1274862A4 EP01923022A EP01923022A EP1274862A4 EP 1274862 A4 EP1274862 A4 EP 1274862A4 EP 01923022 A EP01923022 A EP 01923022A EP 01923022 A EP01923022 A EP 01923022A EP 1274862 A4 EP1274862 A4 EP 1274862A4
Authority
EP
European Patent Office
Prior art keywords
oxidised
phospholipid
mammal
atherosclerosis
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01923022A
Other languages
German (de)
English (en)
Other versions
EP1274862A1 (fr
Inventor
Alan M Fogelman
Mohamad Navab
Susan Hama
Srinivasa T Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/541,468 external-priority patent/US6596544B1/en
Application filed by University of California filed Critical University of California
Publication of EP1274862A1 publication Critical patent/EP1274862A1/fr
Publication of EP1274862A4 publication Critical patent/EP1274862A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
EP01923022A 2000-03-31 2001-03-29 Regulation d'un gene induit par des lipides oxydes dans des cellules humaines de paroi arterielle Withdrawn EP1274862A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53956900A 2000-03-31 2000-03-31
US539569 2000-03-31
US09/541,468 US6596544B1 (en) 2000-03-31 2000-03-31 Functional assay of high-density lipoprotein
US541468 2000-03-31
PCT/US2001/010590 WO2001075168A1 (fr) 2000-03-31 2001-03-29 Regulation d'un gene induit par des lipides oxydes dans des cellules humaines de paroi arterielle

Publications (2)

Publication Number Publication Date
EP1274862A1 EP1274862A1 (fr) 2003-01-15
EP1274862A4 true EP1274862A4 (fr) 2005-06-22

Family

ID=27066136

Family Applications (3)

Application Number Title Priority Date Filing Date
EP01923023A Expired - Lifetime EP1272666B1 (fr) 2000-03-31 2001-03-29 Dosage fonctionnel de lipoproteine haute densite
EP01923022A Withdrawn EP1274862A4 (fr) 2000-03-31 2001-03-29 Regulation d'un gene induit par des lipides oxydes dans des cellules humaines de paroi arterielle
EP05022081A Withdrawn EP1650312A3 (fr) 2000-03-31 2001-03-29 Dosage fonctionnel de lipoprotéine haute densité

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01923023A Expired - Lifetime EP1272666B1 (fr) 2000-03-31 2001-03-29 Dosage fonctionnel de lipoproteine haute densite

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05022081A Withdrawn EP1650312A3 (fr) 2000-03-31 2001-03-29 Dosage fonctionnel de lipoprotéine haute densité

Country Status (9)

Country Link
EP (3) EP1272666B1 (fr)
JP (2) JP4675539B2 (fr)
AT (1) ATE306563T1 (fr)
AU (3) AU4976201A (fr)
CA (2) CA2404000C (fr)
DE (1) DE60113976T2 (fr)
DK (1) DK1272666T3 (fr)
ES (1) ES2250378T3 (fr)
WO (2) WO2001075168A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
ES2346771T3 (es) 2004-10-15 2010-10-20 The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Serv Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso.
CA2654743C (fr) * 2005-07-27 2015-04-07 Technische Universitaet Graz Phospholipides oxydes comportant un fragment de fluorophore et leur utilisation pour determiner la presence d'une enzyme a activite antiatherogene
WO2008021088A2 (fr) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Les salicylanilides renforcent l'administration par voie orale de peptides thérapeutiques
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
EP2682400B1 (fr) 2007-08-28 2017-09-20 Uab Research Foundation Polypeptides de synthèse imitant l'apolipoprotéine E et leurs procédés d'utilisation
CN102271517B (zh) 2008-11-06 2015-04-08 脉管生物生长有限公司 氧化的脂质化合物和其用途
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
WO2018079674A1 (fr) * 2016-10-31 2018-05-03 国立大学法人大阪大学 Procédé de sélection d'un sujet nécessitant un traitement pour la dyslipidémie et réactif pour une telle sélection
WO2018165574A1 (fr) * 2017-03-10 2018-09-13 The Regents Of The University Of California Procédé de diagnostic du risque de maladie inflammatoire par profilage de glycane
CN115151815A (zh) * 2020-02-25 2022-10-04 美迪恩斯生命科技株式会社 核酸药物等的分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020897A1 (fr) * 1996-11-15 1998-05-22 President And Fellows Of Harvard College Modulation de map kinase phosphatase 1 (mkp-1)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5820932Y2 (ja) * 1979-01-27 1983-05-02 財団法人杉山産業化学研究所 過酸化脂質測定のためのｔｂａ試験紙
JPS56117798A (en) * 1980-02-21 1981-09-16 Toyo Jozo Co Ltd Kit for measuring lipoid peroxide
JPS60133368A (ja) * 1983-12-19 1985-07-16 Dai Ichi Pure Chem Co Ltd 免疫測定方法
JPH01231897A (ja) * 1988-03-11 1989-09-18 Fuji Photo Film Co Ltd 乾式グルコース分析要素
US5135716A (en) * 1989-07-12 1992-08-04 Kingston Diagnostics, L.P. Direct measurement of HDL cholesterol via dry chemistry strips
WO1994023302A1 (fr) * 1993-04-07 1994-10-13 The Australian National University Dosage immunologique de lipoproteines humaines a faible densite modifiees par oxydation presentes dans le plasma
RU94044169A (ru) * 1994-12-16 1996-10-20 И.А. Кочетов Многослойный аналитический элемент
US5958714A (en) * 1996-10-02 1999-09-28 Safety Associates, Inc. Test kits for determining at least two specific analytes in foods and other complex matrices
JP3428853B2 (ja) * 1997-04-02 2003-07-22 東北電子産業株式会社 液体試料の抗酸化力を測定するための方法および装置
DE69738503T2 (de) * 1997-06-20 2009-02-26 Leuven Research & Development V.Z.W. Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020897A1 (fr) * 1996-11-15 1998-05-22 President And Fellows Of Harvard College Modulation de map kinase phosphatase 1 (mkp-1)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUFF JENNIFER L ET AL: "Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells: Effect of actinomycin D and antisense oligonucleotides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 1995, pages 7161 - 7166, XP002325494, ISSN: 0021-9258 *
HUANG Y ET AL: "Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. JUL 1999, vol. 19, no. 7, July 1999 (1999-07-01), pages 1600 - 1607, XP002325496, ISSN: 1079-5642 *
LAI K ET AL: "MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE-1 IN RAT ARTERIAL SMOOTH MUSCLE CELL PROLIFERATION", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 7, October 1996 (1996-10-01), pages 1560 - 1567, XP002058893, ISSN: 0021-9738 *
METZLER B ET AL: "Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 11 DEC 1998, vol. 273, no. 50, 11 December 1998 (1998-12-11), pages 33320 - 33326, XP002325495, ISSN: 0021-9258 *
REDDY SRINIVASA ET AL: "Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 17030 - 17035, XP002325497, ISSN: 0021-9258 *
SUBBANAGOUNDER ET AL.: "EVIDENCE THAT PHOSPHOLIPID OXIDATION PRODUCTS AND/OR PLATELET-ACTIVATING FACTOR PLAY AN IMPORTANT ROLE IN EARLY ATHEROGENESIS IN VITRO AND IN VIVO INHIBITION BY WEB 2086", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, no. 85, 20 August 1999 (1999-08-20), pages 311 - 318, XP002951988, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
EP1274862A1 (fr) 2003-01-15
WO2001075168A1 (fr) 2001-10-11
JP4675539B2 (ja) 2011-04-27
EP1650312A3 (fr) 2006-05-17
ATE306563T1 (de) 2005-10-15
CA2404000C (fr) 2010-07-27
DK1272666T3 (da) 2006-02-27
AU4976201A (en) 2001-10-15
AU4976101A (en) 2001-10-15
AU2001249762B2 (en) 2006-03-30
EP1272666B1 (fr) 2005-10-12
EP1650312A2 (fr) 2006-04-26
DE60113976D1 (de) 2006-02-23
CA2404350A1 (fr) 2001-10-11
CA2404000A1 (fr) 2001-10-11
WO2001075170A1 (fr) 2001-10-11
EP1272666A1 (fr) 2003-01-08
JP2003529375A (ja) 2003-10-07
JP2003529775A (ja) 2003-10-07
EP1272666A4 (fr) 2004-09-22
DE60113976T2 (de) 2006-07-27
ES2250378T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
AU4976101A (en) Control of a gene induced by oxidized lipids in human artery wall cells
CN101078719B (zh) 测量仪操作方法及测量仪
Vaughan et al. Oxidative stress reproduces placental abnormalities of preeclampsia
AU696681B2 (en) Method for quantitatively determining cholesterol
NO176293C (no) Metode for å bestemme en ligand i en pröve ved bruk av en optisk bölgeleder og en anordning for utförelse av metoden
EP0348211A3 (en) Visual discrimination qualitative enzyme assay
DE69808071D1 (de) Nachweistest unter benutzung von magnetteilchen
SE9802402D0 (sv) Method of diagnosing cardiovascular disease and early atherosclerosis
DE59812075D1 (de) Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
MX9604417A (es) Deteccion de analitos.
WO1998059068A1 (fr) Procede servant a analyser des specimens biologiques afin de rechercher des substances contenues dans leurs constituants et reactif utilise dans ce procede
DE69331585D1 (de) Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür
ATE271222T1 (de) Kit und verfahren zur bestimmung des redox-status im urin
GB2237108A (en) Assay for enzyme activity
AU3571901A (en) Electrochemical method for detecting nucleic acids
DK0790494T3 (da) Flerlaget testmiddel
Cominacini et al. The need for a ‘free radical initiative’
Glick The future of clinical microchemical analysis.
JPS5564800A (en) Method and reagent for determination of acyl coenzyme a
Näslund et al. Release of small amounts of free fatty acids from human adipocytes as determined by chemiluminescence.
Feltus et al. Detection of biotin in individual sea urchin oocytes using a bioluminescence binding assay
AU557883B2 (en) Specimen slide for occult blood testing and test kit for occult blood in gastric fluid
Donaghy Autonomous Mathematical Models: Constructing Theories of Metabolic Control
Nielsen Study Questions Determination of Oxygen Demand
ATE222960T1 (de) Auf enzym-gegründetes assay zur bestimmung der wirkung von exogenen und endogenen faktoren auf zellenergie-bildung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090328

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1052373

Country of ref document: HK